There have been significant advances in the development of new targeted therapies for CC such as IDH1 inhibitor for IDH1 mutant tumors (106), and FGFR inhibitors for tumors harboring FGFR2 fusions (107, 108). Here, FGFR2 is linked to cholangiocarcinoma.